Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

Marie Skłodowska-Curie Action · Running

radio3D Next-Generation Radiopharmaceuticals for Glioblastoma and Pancreatic Cancer: A 3D Perspective

Coordinator
Agencia Estatal Consejo Superior De Investigaciones Cientificas, Spain
Runs
1 January 2027 to 31 December 2030
Status
Running
EU funding
€4.4m
Total cost
—
Partners
21 organisations in 9 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101311799

What the project is doing

In the project's own words, from its summary on CORDIS.

Radiopharmaceuticals have become essential for advancing cancer treatment. The radio3D project aims to innovate this field by combining radiotherapy with nanomaterials and 3D disease models. This approach seeks to enhance therapeutic strategies while reducing reliance on animal testing for cancer research. The radio3D project aims to enhance cancer therapy efficacy and safety by employing clinically approved nanomaterials and radioisotopes for imaging and treatment of glioblastoma and pancreatic cancer.

Advanced 3D tumour models, such as organoids and bioprinted structures, will be utilised to mimic the tumour microenvironment, enabling efficient drug evaluation, investigation of tumour-stroma interactions, and promotion of personalised medicine while minimising animal testing. The initiative comprises four interdisciplinary work packages, each focusing on training, research, dissemination, and management. This structure promotes cooperation amongst various professionals, including chemists, physicists, biologists, physicians, and entrepreneurs. radio3D brings together 21 groups from academia, industry, and hospitals to elevate cancer treatment research, innovation, and ethical standards.

Through the interdisciplinary scientific and intersectoral approach and an extensive and targeted training program radio3D is dedicated to cultivating a new generation of interdisciplinary scientists skilled in nanotechnology, radiolabelling, biomedical imaging, and advanced tumour modelling. By harnessing the synergistic potential of nanomaterials and radiopharmaceuticals, while significantly reducing animal testing, radio3D will advance the field by introducing innovative chemistries and alternative methods for understanding cancer biology to establish a groundbreaking benchmark in nanomedical research, transforming the future of oncology and improving therapeutic outcomes.

Topics

Who is involved

OrganisationCityCountryRole
Agencia Estatal Consejo Superior De Investigaciones CientificasMadridSpainCoordinator
Klinikum Der Universitaet RegensburgRegensburgGermanyAssociatedpartner
Technische Hochschule DeggendorfDeggendorfGermanyParticipant
Universitaet RegensburgRegensburgGermanyParticipant
Ethniko Kai Kapodistriako Panepistimio AthinonAthinaGreeceParticipant
Asociacion Centro De Investigacion Cooperativa En Biomateriales- Cic BiomaguneSan SebastianSpainParticipant
Asociacion Instituto De Investigacion Sanitaria BiogipuzkoaDonostia-San SebastianSpainAssociatedpartner
Bbd Biophenix SLSan SebastianSpainAssociatedpartner
Fundacion Centro De Tecnologias De Interaccion Visual Y Comunicaciones VicomtechDonostia San SebastianSpainAssociatedpartner
Servicio Madrileno De SaludMadridSpainAssociatedpartner
Universidad Complutense De MadridMadridSpainAssociatedpartner
Universidad Del Pais Vasco/ Euskal Herriko UnibertsitateaLeioaSpainAssociatedpartner
Azienda Ospedaliero Universitaria delle MarcheAnconaItalyAssociatedpartner
Universita Degli Studi Di Roma La SapienzaRomaItalyParticipant
Universita Politecnica Delle MarcheAnconaItalyParticipant
Technische Universiteit DelftDelftNetherlandsAssociatedpartner
Norgenotech ASOsloNorwayParticipant
Altium International Sp. z o. o.WarszawaPolandAssociatedpartner
Gdanski Uniwersytet MedycznyGdanskPolandParticipant
Linkopings UniversitetLinkopingSwedenParticipant
King's College LondonLondonUnited KingdomParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI